Form 8-K Aevi Genomic Medicine, For: Jan 02

January 2, 2019 4:33 PM

  

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

Current Report

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

January 2, 2019

Date of Report (Date of earliest event reported)

 

AEVI GENOMIC MEDICINE, INC.

(Exact name of registrant as specified in its charter)

 

Delaware 1-35112 98-0217544

(State or other jurisdiction of 

incorporation or organization)

(Commission File Number)

(I.R.S. Employer

Identification No.)

 

435 Devon Park Drive, Suite 715

Wayne, Pennsylvania 19087

(Address of principal executive offices, zip code)

 

(610) 254-4201

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

   

 

 

 

 

  

Item 8.01.    Other Events.

 

On January 2, 2019, Aevi Genomic Medicine, Inc. issued a press release announcing top-line results from its ASCEND clinical trial (Part A & B). A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:
   
99.1 Aevi Genomic Medicine, Inc. Press Release dated January 2, 2019

   

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AEVI GENOMIC MEDICINE, INC.  
     
     
  By: /s/ Michael F. Cola  
    Name: Michael F. Cola  
    Title: President and Chief Executive Officer  

 

Date: January 2, 2019

  

 

 

Exhibit 99.1

 

Aevi Genomic Medicine Announces Top-Line Results from Placebo-Controlled ASCEND Trial (Parts A & B) of AEVI-001 in Children with ADHD

 

PHILADELPHIA, January 2, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (“the Company”) today announced that the ASCEND trial, a genomically-guided Phase 2 double-blind, placebo-controlled clinical trial of orally-administered AEVI-001 (100 – 400 mg BID) in children aged 6 – 17 with Attention Deficit Hyperactivity Disorder (ADHD) with an mGluR copy number variant (Part A) or without an mGluR copy number variant (Part B), did not achieve statistical significance on the primary endpoint of reduction of ADHD-RS in either Part A or Part B after 6 weeks of treatment with AEVI-001. AEVI-001 was safe and well tolerated. Reported adverse events were minimal and similar across both Part A and Part B treatment groups.

 

“We are very disappointed that the ASCEND trial did not achieve its primary endpoint.” said Michael F. Cola, CEO of Aevi Genomic Medicine. “We plan to conduct a full review of the data with our scientific advisers in the coming days and consider our options. We want to thank the investigators, study coordinators and the entire Aevi team for their hard work on this innovative study. We also especially want to thank the patients and their families for their participation. We remain committed to our mission of bringing novel targeted therapies to children with serious rare and orphan disease. We will continue to focus on our pipeline of additional molecules, including AEVI-002 for severe pediatric-onset Crohn’s Disease and AEVI-005 for an undisclosed autoimmune orphan disease, both partnered with Kyowa Hakko Kirin. In the near-term, we anticipate reducing the scope of our operations to preserve our net working capital, which was approximately $5 million (unaudited) as of December 31, 2018.”

 

About Aevi Genomic Medicine, Inc.

 

Aevi Genomic Medicine, Inc. is dedicated to unlocking the potential of genomic medicine to translate genetic discoveries into novel therapies. Driven by a commitment to patients with pediatric onset life-altering diseases, the Company’s research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children’s Hospital of Philadelphia (CHOP).

 

About AEVI-001

 

AEVI-001 is an oral non-stimulant pan selective activator/modulator of mGluRs. The molecule has excellent pharmacokinetic and metabolic profiles and crosses the blood brain barrier.

 

 

 

 

Aevi Genomic Medicine remains committed to the development of AEVI-001 as a potential treatment for a sub-population of Attention Deficit Hyperactivity Disorder (ADHD) patients with genetic mutations that disrupt the mGluR network. In the US, the CDC estimates that 6.4 million children 4-17 years of age (11%) have ever been diagnosed with ADHD. Many ADHD patients remain unsatisfied with existing therapies, particularly with respect to safety, tolerability and treatment of comorbidities.

 

AEVI-001 is an investigational agent that has not been approved by the US FDA or any other regulatory agencies.

  

About the ASCEND Trial

 

The AEVI-001-ADHD-202 study (ASCEND) was a 2-part, 6-week, double-blind, dose-optimization, parallel-group study in children and adolescents (ages 6-17 years) with attention deficit hyperactivity disorder (ADHD) with and without copy number variants (CNVs) in specific genes implicated in glutamatergic signaling and neuronal connectivity. Part A included subjects determined to have one of 8 specific gene mutation(s) implicated in glutamatergic signaling and neuronal connectivity. Part B included subjects who did not have CNVs in any of the specific gene mutation(s) implicated in glutamatergic signaling and neuronal connectivity. Once subjects were confirmed as eligible for each part of the study, they were randomized to one of two treatment groups (AEVI-001 or placebo) in a 1:1 ratio.

 

In Part A of the study, 69 unique subjects were enrolled. In Part B of the study, 109 unique subjects were enrolled. After screening and washout of prior ADHD therapy, subjects entered a dose optimization phase wherein doses were titrated to a dose up to 400 mg BID. Subjects then entered a maintenance phase with weekly follow-up for up to 6 weeks.

 

 

 

 

Forward-looking Statements

 

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, status and timing of clinical trials, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.

 

CONTACT:

 

Aevi Genomic Medicine, Inc.

Brian Piper

Brian.Piper@aevigenomics.com

 

Westwicke Partners

Chris Brinzey

339-970-2843

Chris.brinzey@westwicke.com

  

 

 

 

 

 

 

 

 

 

 

Categories

SEC Filings

Next Articles